FDA approves Alzheimer’s drug shown to slow cognitive decline in early-stage disease The FDA on Friday approved a new Alzheimer’s treatment that moderately slows cognitive decline in people in the early stages of the disease. Eisai, which also developed the first symptomatic treatment for Alzheimer’s 25 years ago, hasn’t yet disclosed the price of the drug, called Leqembi. Analysts expect it to be in the mid-$20,000 range for a year’s treatment. Read More If you’d like to stop receiving these alerts, click on the "update email preferences" link below. | 
No comments